Drug combinations can expand therapeutic options and address cancer's resistance. However, the combinatorial space is enormous precluding its systematic exploration. Therefore, synergy prediction strategies are essential. We here present an approach to prioritise drug combinations in high-throughput screens and to stratify synergistic responses. At the core of our approach is the observation that the likelihood of synergy increases when targeting proteins with either strong functional similarity or dissimilarity. We estimate the similarity applying a multitask machine learning approach to basal gene expression and response to single drugs. We tested 7 protein target pairs (representing 29 combinations) and predicted their synergies in 33 breast cancer cell lines. In addition, we experimentally validated predicted synergy of the BRAF/insulin receptor combination (Dabrafenib/BMS-754807) in 48 colorectal cancer cell lines. We anticipate that our approaches can be used for prioritization of drug combinations in large scale screenings, and to maximize the efficacy of drugs already known to induce synergy, ultimately enabling patient stratification.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265486PMC
http://dx.doi.org/10.1038/s41540-020-0136-xDOI Listing

Publication Analysis

Top Keywords

drug combinations
12
functional similarity
8
cancer cell
8
cell lines
8
synergy
5
stratification prediction
4
drug
4
prediction drug
4
drug synergy
4
synergy based
4

Similar Publications

Background: This study assessed stress distributions in simulated mandibular molars filled with various materials after the removal of fractured instruments from the apical thirds of the root canals.

Methods: Finite element models of the mesial and distal root canals were created, where fractured instruments were assumed to be removed using a staging platform established with a modified Gates-Glidden bur (Woodpecker, Guangxi, P.R.

View Article and Find Full Text PDF

Mechanical behavior of external root resorption cavities restored with different materials: a 3D-FEA study.

BMC Oral Health

January 2025

Faculty of Dentistry, Department of Endodontics, Ondokuz Mayis University, Samsun, Kurupelit, 55139, Turkey.

Background: The aim was to evaluate the stresses in teeth, with external root resorption (ERR) restored with different materials using finite element analysis (FEA).

Methods: In this study, a Micro-CT scan was conducted on a prepared maxillary central tooth. DICOM-compatible images obtained from the sections were converted into stereolithography format using Ctan software.

View Article and Find Full Text PDF

A comparative study of polydopamine vs. glass ionomer cement for adhesion mechanisms on enamel and dentin using SEM and shear bond strength evaluation.

Sci Rep

January 2025

Department of Conservative Dentistry and Endodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, 600077, India.

Polydopamine (PD), inspired by the wet adhesion mechanism of mussel foot proteins, has emerged as a promising adhesive material with wide-ranging applications. This study aimed to compare the adhesive properties of PD and Glass Ionomer Cement (GIC) on enamel and dentin substrates, evaluating PD's potential as an alternative adhesive in dental practice. A total of 120 human premolars were prepared, with 80 teeth allocated for Scanning Electron Microscopy (SEM) analysis and 40 teeth reserved for shear bond strength testing.

View Article and Find Full Text PDF

Clinical trials demonstrate the short-term efficacy of dual CFTR modulators, but long-term real-world data is limited. We aimed to investigate the effects of 24-month lumacaftor/ivacaftor (LUM/IVA) therapy in pediatric CF patients (pwCF). This observational study included pwCF homozygous for F508del mutation treated between 2021 and 2023.

View Article and Find Full Text PDF

A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.

Clin Breast Cancer

December 2024

Medical Oncology and Palliative Care, Department of Medicine, Breast Cancer Disease Oriented Team, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792-3252.

Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients with ER+, PgR+/-, HER2- metastatic breast cancer. This study was terminated early and herein, we report patient characteristics, and outcomes.

Methods: Eligibility criteria included disease progression on ≥2 lines of prior therapy, ECOG performance status ≤ 2, measurable disease per RECIST 1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!